N/A
Manufactured by Actavis Pharma, Inc.
13,437 FDA adverse event reports analyzed
Last updated: 2026-04-15
FOSAPREPITANT is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Actavis Pharma, Inc.. The most commonly reported adverse reactions for FOSAPREPITANT include DYSPNOEA, INFUSION RELATED REACTION, ALOPECIA, FATIGUE, HYPERSENSITIVITY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FOSAPREPITANT.
Out of 1,556 classified reports for FOSAPREPITANT:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 13,437 FDA FAERS reports that mention FOSAPREPITANT. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, INFUSION RELATED REACTION, ALOPECIA, FATIGUE, HYPERSENSITIVITY, PYREXIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Actavis Pharma, Inc. in connection with FOSAPREPITANT. Always verify the specific product and NDC with your pharmacist.